|
Synonyms: CD20-TCB (2:1) | Columvi® | glofitamab-gxbm | RG-6026 | RG6026
glofitamab is an approved drug (FDA & EMA (2023))
Compound class:
Antibody
Comment: Glofitamab (RG6026) is a bispecific antibody that concomitantly binds to CD20 (on malignant B cells) and CD3ε (on T cells) [1-2]. It was designed to promote T cell-mediated killing of B cell lymphomas [3,5]. It is bivalent for CD20 and monovalent for CD3ε and has an extended circulatory half-life compared to obinutuzumab.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Glofitamab is under clinical investigation as a monotherpay and in combination with other agents for the treatment of non-Hodgkin lymphomas. It received its first national approval in Canada in March 2023 [4]. The FDA approved glofitamab in June 2023 as a treatment for previously treated relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) arising from follicular lymphoma. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03467373 | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | Phase 1 Interventional | Hoffmann-La Roche | ||
| NCT04408638 | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 Interventional | Hoffmann-La Roche | ||
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1/Phase 2 Interventional | Hoffmann-La Roche | ||
| NCT05219513 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1 Interventional | Hoffmann-La Roche | ||
| External links |
|
For extended ADME data see the following: European Medicines Agency (EMA) |
